Darwin AG, a European healthcare company specializing in human genetics and personalized products, has officially changed its name to Novogenia AG following the registration of the corresponding amendment to the Articles of Association in the Commercial Register. The name change, approved at the Annual General Meeting on June 26, 2026, is part of a strategic process to unify the company’s market presence and reinforce its focus on its core operating brand.
The company’s wholly owned subsidiary, Novogenia GmbH, has been the primary driver of operational business and future growth. Novogenia GmbH has been active in human genetics for many years, developing and selling personalized products based on genetic analysis. The Novogenia brand represents in-depth scientific expertise and ongoing technological innovation, which will now be reflected at the corporate level.
According to Dr. Daniel Wallerstorfer, CEO of Novogenia AG, the renaming enhances visibility and recognition while reinforcing the company’s ambition to become a leading international provider of personalized healthcare and longevity solutions. “Novogenia has been at the heart of our operational business and our international market presence for many years. By operating under the name Novogenia AG, we are consistently unifying our corporate and brand identities,” he stated.
The name change simplifies the corporate structure and communication, creating a consistent image across all relevant target groups, including customers, partners, investors, and the capital market. It supports a clearer positioning and strengthens the company’s international appeal. Importantly, the change has no impact on the company’s strategic direction, business model, or operational activities. The stock market listing and existing shareholder rights remain unchanged.
Novogenia AG, headquartered in Munich, Germany, is a European healthcare company active in human genetics and the development of personalized products based on genetic analysis. Its genetic analyses, conducted in its own laboratory, are used for diagnosis, treatment, and prevention of diseases, as well as for producing individually tailored nutritional supplements and cosmetics. The company also partners with physicians, therapists, pharmacists, nutritionists, and fitness trainers to optimize treatment based on genetic predispositions. Additionally, Novogenia holds investments in innovative biotech, healthcare, and life sciences companies.
The unification of corporate and brand identity under Novogenia AG is expected to enhance the company’s presence in the capital market and among international stakeholders. For more information, visit https://novogenia.com/novogenia-ag.
